พบ "Public health policy"ทั้งหมด 1,230 ผลลัพธ์
เรียงลำดับตาม
ฮ - ก

Coverage Decisions and the Court: A Public Health Perspective on Glucosamine Reimbursement in Thailand (2016)

Sripen Tantivess & Viroj Tangcharoensathien Abstract Thailand achieves universal health coverage through the introduction of 3 benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these sche

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand

ABSTRACT Objectives: This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand. Design: Economic evaluation using a decision-analytical model. Setting:

Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand (2015)

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. (2014)

Background: In Thailand, there has been no economic evaluation study of adjuvant chemotherapy for stage III colon cancer patients after resection. Objective: This study aims to evaluate the cost-utility of all chemotherapy regimens currently used in Thailand compared with the adjuvant 5-fluorouracil

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? (2013)

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Cost-effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients

Systemic sclerosis (SSc) patients often become refractory to proton pump inhibitors (PPI)—a standard treatment for gastroesophageal reflux disease (GERD)—and intolerant to PPI in combination with domperidone. PPI with alginic acid is an alternative treatment option, but alginic acid is costly. We

Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India

ABSTRACT Objective Despite treatment availability, chronic hepatitis C virus (HCV) public health burden is rising in India due to lack of timely diagnosis. Therefore, we aim to assess incremental cost per quality-adjusted life year (QALY) for one-time universal screening followed by treatment of

Cost-effectiveness analysis of typhoid vaccination in Lao PDR

Abstract Background Typhoid vaccination has been shown to be an effective intervention to prevent enteric fever and is under consideration for inclusion in the national immunization program in Lao PDR. Methods A cost-utility analysis was performed using an age-structured static decision tree

Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand (2008)

Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Suphachai Chirakup1,2 Nathorn Chaiyakunapruk1,3,4 Usa Chaikledkeaw5,6 Petcharat Pongcharoensuk5 Boonsong Ongphiphadhanakul7 Stephane Roze8 William J. Val

Cost utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand

Objective: This study aims to compare the lifetime costs and health outcomes of both first-line and sequential combination treatments with standard treatment for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) (PAH-CHD) patients. Methods: A cost-utility analysis
10 / หน้า